J. Robert Davis - Personal Injury Attorney in San Antonio The Law Offices of J. Robert Davis, PC is a San Antonio personal injury law firm. We provide experienced attorneys to fight for our clients injured by truck car accidents, boating motorcycle accidents, injuries due to drugs medical devices and other personal injuries. Practice Areas Motor vehicle accidents Personal injury Workplace injury Drug side effects Medical devices Defective products By: Doug Mansfield … Continue reading →

Mainstream Media and Drugs Are you aware of what is happening with drugs in this country and the side effects they have? Unfortunately many of us do not know the damaging effects of certain drugs because the FDA is not requiring these companies to put the warnings on the their labels. By: DivineSpine … Continue reading →

WASHINGTON (AP) The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison. Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy. "This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer." Cobleigh helped conduct the key studies of the drug at the Chicago facility. The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form … Continue reading →

By Robert Weisman, Globe Staff Federal regulators Friday morning said they approved T-DM1, a promising new breast cancer therapy with potentially serious side effects, for sale in the United States. Key components of the drug were developed by Waltham biotechnology company ImmunoGen Inc., but the drug is being marketed by its partner, the Genentech division of Swiss drugmaker Roche AG, under the brand name Kadcyla. Kadcyla was approved for sale to patients with HER2-positive metastatic breast cancer, an aggressive form of the disease, who have received prior treatment with the drug Herceptin along with a chemotherapy. It is the first antibody-drug conjugate for the disease okayed by the Food and Drug Administration. The approval comes two and a half years after the FDA surprised ImmunoGen, Genentech, and the patient community by rebuffing a bid to give T-DM1 fast-track status in a refuse to file letter that declined to accept an application for accelerated review. While many patients have been taking the drugs in clinical trials or through so-called compassionate use programs, others have been unable to obtain it, sparking protest against the FDA. In a statement Friday, the FDA did not address that controversy. But it said Kadcyla is being … Continue reading →

By Robert Weisman, Globe Staff Federal regulators Friday morning said they approved T-DM1, a promising new breast cancer therapy with potentially serious side effects, for sale in the United States. Key components of the drug were developed by Waltham biotechnology company ImmunoGen Inc., but the drug is being marketed by its partner, the Genentech division of Swiss drugmaker Roche AG, under the brand name Kadcyla. Kadcyla was approved for sale to patients with HER2-positive metastatic breast cancer, an aggressive form of the disease, who have received prior treatment with the drug Herceptin along with a chemotherapy. It is the first antibody-drug conjugate for the disease okayed by the Food and Drug Administration. The approval comes two and a half years after the FDA surprised ImmunoGen, Genentech, and the patient community by rebuffing a bid to give T-DM1 fast-track status in a refuse to file letter that declined to accept an application for accelerated review. While many patients have been taking the drugs in clinical trials or through so-called compassionate use programs, others have been unable to obtain it, sparking protest against the FDA. In a statement Friday, the FDA did not address that controversy. But it said Kadcyla is being … Continue reading →

With pharmaceutical companies having to state the negative side effects of taking their products, drug commercials are often deadly comical. They usually go something like this: If you cant sleep, take medication X and you will sleep like a baby. Warning, side effects may include loss of consciousness and bladder, heart and lung malfunctions. Death could occur with frequent use. Interestingly, the acknowledged potential and serious negative side effects of drugs dont seem to adversely impact sales. People, it would seem, like their drugs and are willing to turn a blind eye to any potential negative outcome, until, of course, their lives become threatened by one of the serious side effects, and then they will likely look to sue the drug company. Much like pharmaceutical companies, congressional Republicans over the past four years have been selling debt and deficit remedies with serious side effects for the economy and the American people, and that is why I am rooting for the March 1 sequestration deadline and the automatic spending cuts it triggers to come to pass, because as the old saying goes, who feels it, knows. The sequestration deadline came out of the Budget Control Act of 2011. The act cut … Continue reading →